Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy As First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
Value in Health Regional Issues（2024）
Key words
advanced renal cell carcinoma,cost-effectiveness analysis,ipilimumab Japan,nivolumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined